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Abstract: Design of an optimal surface biofunctionalization still remains an important 
challenge for the application of biosensors in clinical practice and therapeutic follow-up. 
Optical biosensors offer real-time monitoring and highly sensitive label-free analysis, 
along with great potential to be transferred to portable devices. When applied in direct 
immunoassays, their analytical features depend strongly on the antibody immobilization 
strategy. A strategy for correct immobilization of antibodies based on the use of 
ProLinker™ has been evaluated and optimized in terms of sensitivity, selectivity, stability 
and reproducibility. Special effort has been focused on avoiding antibody manipulation, 
preventing nonspecific adsorption and obtaining a robust biosurface with regeneration 
capabilities. ProLinker™-based approach has demonstrated to fulfill those crucial requirements 
and, in combination with PEG-derivative compounds, has shown encouraging results for 
direct detection in biological fluids, such as pure urine or diluted serum. Furthermore,  
we have implemented the ProLinker™ strategy to a novel nanoplasmonic-based biosensor 
resulting in promising advantages for its application in clinical and biomedical diagnosis.  
Keywords: antibody immobilization; ProLinker™; direct immunoassay; SPR biosensor; 
nanoplasmonic biosensor; gold nanodisks; clinical diagnosis 
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1. Introduction 
During the last decades, biosensors have emerged as essential tools in biomedical applications, 
offering exceptional advantages over conventional clinical techniques for diagnostics and therapy 
monitoring. Biosensing platforms and optical biosensors in particular provide rapid, reproducible and 
highly sensitive detection. They allow label-free analysis (i.e., photonic and plasmonic biosensors) and 
real-time monitoring of biological events. They have also shown exceptional potential for integration 
in lab-on-a-chip devices [1,2]. Among optical biosensors, surface plasmon resonance (SPR) devices 
have been established as routine analytical instruments due to the simplicity and versatility of the 
technique. Nevertheless, the increasing evolution of nanotechnology has led to novel biosensing 
techniques based on plasmonic nanostructured surfaces (i.e., nanoplasmonics) which offer important 
advantages in terms of sensitivity, high throughput capabilities, integration and miniaturization [3]. So 
far, most research in this field has been directed towards fabrication and evaluation of the 
nanostructured substrates. The optimization of the biofunctionalization on the other hand is only 
partially addressed, limiting further development of reliable point-of-care devices with well-defined 
clinical applications. The challenge of an optimal biofunctionalization of the transducer is particularly 
relevant for immunosensors in direct configuration (i.e., direct immunoassay) due to the complexity  
of retaining the biological activity of the antibodies (Ab) during their immobilization on a solid  
support [4]. The direct immunoassay should be the preferred format for diagnosis since it permits  
one-step analyte detection and, ideally, direct measurements from biological fluids. To fulfill this 
unmet need and to improve the overall efficiency of the process, many biofunctionalization strategies 
for antibody immobilization have been studied [4,5]. The main requirements taken into account are 
related to orientation control, the minimization of the chemical modification of the Ab and the 
reduction of the nonspecific adsorption onto the surface. Some widely used methodologies lead to random 
Ab orientation, decreasing the binding affinity due to blocking of the antigen recognition sites. These 
include physical/electrostatic adsorption, covalent linking to self-assembled monolayers or high 
affinity coupling between streptavidin-coated surfaces and biotinylated antibodies [4,6–8]. Direct 
immobilization of Fab fragments of the antibody [9] or coupling through the carbohydrate residues in 
the Fc part of the antibody also allow proper orientation [10]. However, both approaches require 
chemical modification of antibodies, which can also alter the specific binding sites and worsen the 
affinity. The use of Protein A or Protein G, which bind to the Fc region of antibodies [11,12], also leads 
to an oriented arrangement. This strategy can result in a significantly higher fraction of active 
antibodies since no previous modification is required. However the antibody-Protein A/G interaction 
can suffer instability under certain conditions. Organic molecules such as metal complexes [13] or 
calixarene derivatives [14] have also demonstrated their usefulness to immobilize the antibody with 
proper orientation avoiding chemical modification of the biomolecule. Unfortunately, in many cases 
these strategies are not always optimized and assessed for label-free detection in biological fluids. 
In this work, we aimed to achieve a stable and robust antibody-coated surface for protein biomarker 
detection in biological fluids using label-free optical biosensors. We have dedicated our attention to a 
calixarene-based antibody immobilization strategy (ProLinker™ B). ProLinker™ B is a cup-shaped 
molecule first synthesized by Lee et al. [14], which permits binding proteins in a uniform and tight 
manner. Moreover, it has shown the ability to efficiently orientate and immobilize antibodies. 
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We have focused on assessing the ProLinker™-based strategy for plasmonic and nanoplasmonic 
sensor surfaces. Employing a SPR platform as a model label-free biosensor, we have carried out a 
preliminary comparison between different antibody immobilization strategies (i.e., conventional covalent 
binding, Protein G-mediated capture and ProLinker™ strategy). We have evaluated the efficiency of 
the immobilization and the final sensitivity on direct immunoassays. The strategy has been applied  
for the direct detection of protein biomarkers with demonstrated relevance in clinical field, such  
as the human Chorionic Gonadotropin (hCG), the C-Reactive Protein (CRP) and the Focal Adhesion 
Kinase (FAK). A more in depth effort has been dedicated to those features barely approached so far 
with Prolinker™ such as the robustness and stability of the biosurface and the prevention of undesired 
nonspecific events in complex matrices, since the final goal is the direct detection from biological 
samples such as blood, serum or urine. This latter aspect has been particularly relevant in order to 
implement the biofunctionalization methodology on nanoplasmonic surfaces (i.e., gold nanodisks on 
glass substrates). Besides studying the influence of the substrate on nonspecific adsorption, also 
comparative sensitivity studies have been performed with conventional SPR, in order to demonstrate 
the potential of this Localized Surface Plasmon Resonance (LSPR)-based biosensing scheme. 
2. Experimental Section 
2.1. Reagents  
Organic solvents for chip cleaning (trichloroethylene, acetone and ethanol), sulfuric acid, hydrogen 
peroxide and hydrochloric acid were provided by Panreac (Barcelona, Spain). Chloroform, alkanethiols 
for SAM formation (16-mercaptohexadecanoic acid (MHDA) and 11-mercaptoundecanol (MUOH)), 
reagents for carboxylate group activation (1-ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) and N-hydroxysuccinimide (NHS)), ethanolamine, crosslinking molecule (bis(sulfosuccinimidyl) 
suberate, BS
3
), glycine, Tween 20 and bovine serum albumin (BSA) were purchased from Sigma 
Aldrich (Steinhem, Germany). 
Human Chorionic Gonadotropin (hCG) was obtained from Abcam (Cambridge, UK), Focal Adhesion 
Kinase (FAK) was obtained from OriGene (Rockville, MD, USA) and C-Reactive Protein (CRP)  
from AntibodyBcn (Barcelona, Spain). Monoclonal antibody anti-hCG was a kind gift by the  
Dr. Jose Miguel Rodríguez Frade from the Department of Immunology and Oncology, National Center 
of Biotechnology (CNB-CSIC, Madrid, Spain). The antibody was purified by affinity chromatography 
using 1 mL HiTrap™ Protein G and PD-10 Desalting Columns (GE Healthcare, Uppsala, Sweden). 
Monoclonal antibody anti-FAK was supplied by BD Biosciences (San Diego, CA, USA) and 
monoclonal antibody anti-CRP was from AntibodyBcn. Recombinant Protein G was from Merck 
(Darmstadt, Germany). ProLinker™ B was provided by Proteogen Inc. (Seoul, Korea).  
Copolymer poly-(L-lysine)-graft-PEG (PLL-PEG, MW~75.000 g/mol) was from SuSoS (Dübendorf, 
Switzerland) and diamine-PEG (NH2-PEG-NH2, MW 10.000 g/mol) from Laysan Bio (Arab, AL, 
USA). Amine-dextran (MW 10.000 g/mol) was obtained from Invitrogen (Eugene, OR, USA). 
SuperBlock
®
 Blocking Buffer in TBS was purchased from Fisher Scientific (Madrid, Spain). Human 
serum was from Sigma-Aldrich. Urine was from healthy human donors. 
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Buffers used in this work are the following: PBS buffer (10 mM phosphate with 137 mM NaCl  
and 2.7 mM KCl, pH 7.4); acetate buffer (10 mM, pH 5.0); MES buffer (0.1 M, pH 5.4); PBST  
(PBS buffer + 0.5% Tween 20) and high-blocking buffer (HBB) (PBS buffer + 500 mM NaCl +  
200 µg/mL BSA + 500 µg/mL amine-dextran + 0.5% Tween 20). 
2.2. Biosensing Platforms Description  
The optimization and comparison study was performed using a homemade SPR sensor platform 
based on the Kretschmann configuration, monitoring the binding events in real time. A polarized light 
of 670 nm is divided in two identical beams though a light splitter (5 mm/side cube) which are focused 
to the backside of the gold sensing chip (glass surface coated with 2 nm of chromium and 45 nm of 
gold, 10 × 10 × 0.3 mm, from Ssens, (Enschede, The Netherlands). Measurements are performed at a 
fixed angle of incidence and variations of the refractive index (RI) due to biointeraction events 
occurring at the sensing surface are detected as changes in the reflected light intensity by a 
multielement photodiode. The flow system consists of two flow cells (300 nL each) for independent 
analysis. The device incorporates all optics, electronics and fluidics components necessary to operate 
autonomously. Sensograms reproduce the binding event by monitoring the increase (or decrease in case 
of unbinding events) of the intensity of the reflected light (ΔRpp) vs. time. This change of the intensity 
of the reflected light is directly related to changes in the RI of the dielectric medium caused by mass 
changes on the metallic surface. 
On the other hand, the nanoplasmonic biosensor is based on short-ordered arrays of gold nanodisks 
whose LSPR is excited in total internal reflection (θ = 70°) [15]. The arrays of gold nanodisks  
(D = 100 nm, H = 20 nm (Ti/Au = 1/19 nm)) were fabricated on glass substrates via hole-mask 
colloidal lithography (HCL) [16], assuring a LSPR wavelength (λLSPR) close to 700 nm. The substrates 
were clamped between a trapezoidal glass prism contacting the sample through RI matching oil  
(n ≈ 1.512) and a custom-made flow cell (volume = 4 µL), which is connected to a microfluidic system 
consisting on a syringe pump with adjustable pumping speed that ensured a constant liquid flow and a 
manually operated injection valve. The biosensing surfaces were excited by a collimated halogen light 
source set in TE polarization for gold nanodisks and TM polarization for gold films (note that for the 
comparative SPR vs. LSPR sensitivity studies, this same setup was employed, either as an SPR sensor 
or as an LSPR sensor). The light reaches the substrates at a fixed angle of 70° through the prism  
and the reflected light is collected and fiber-coupled to a CCD spectrometer. Tracking of the real-time 
resonance peak position was achieved via polynomial fit using homemade readout software. The 
obtained sensograms show the displacement of the λ(L)SPR to lower energy (higher RI, binding event) or 
higher energy (lower RI, unbinding event). The λ(L)SPR is therefore directly related to mass changes on 
the gold surfaces. In both LSPR and SPR biosensors, experiments were carried out keeping a constant 
flow rate of 15 µL/min for immobilization and target recognition, and of 30 µL/min for regeneration. 
Total sample analysis was 20 min (30 min when including the regeneration of the biosurface). 
2.3. Antibody Immobilization Strategies  
Sensor chip cleaning procedure prior to biofunctionalization consisted of successive washing steps 
in trichloroethylene, acetone, ethanol and MilliQ water. In the case of SPR chips, the surface was then 
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immersed in freshly prepared piranha solution (H2SO4-H2O2 3:1) for 15 s, rinsed with water and dried 
under nitrogen flux. For gold nanodisks substrates the piranha step was replaced for 15 min under 
ozone generator. 
2.3.1. Covalent Strategy 
Formation of a mixed alkanethiols self-assembled monolayer (SAM) was carried out ex-situ, by 
coating the gold chip overnight with a mixed solution of MHDA/MUOH (molar ratio of 1:20 and total 
alkanethiol concentration of 250 µM in EtOH). The chip was then mounted in the SPR platform in 
order to immobilize the antibodies by covalent binding to the carboxylic groups of the mixed SAM. 
Activation of carboxylate groups was performed by injecting a 0.2 M EDC/0.05 M NHS solution  
in MES buffer; then, antibody dissolved in PBS buffer was injected, followed by 1 M ethanolamine 
solution (pH 8.5) to deactivate unreacted carboxylic groups.  
2.3.2. Protein G Strategy 
Protein G diluted in PBS (50 µg/mL) was immobilized by covalent binding to the mixed alkanethiol 
SAM formed as described above. Then, the antibody was injected in acetate buffer and once captured 
by Protein G, the crosslinker BS
3
 dissolved in PBS was flowed (1,000-fold molar excess with respect 
to antibody concentration). In order to quench crosslinking reaction and remove unreacted molecules, 
100 mM glycine-HCl solution (pH 2.7) was injected.  
2.3.3. ProLinker™ Strategy 
ProLinker™ layer was formed by incubating the gold chip in 3 mM ProLinker™ B solution in 
chloroform for 1 h at room temperature. Next, the surface was rinsed with chloroform, acetone, ethanol 
and water; dried with N2 flux and mounted on the sensor. Antibody solution in PBS buffer was 
injected followed by a BSA solution (100 µg/mL in PBS) to block remaining reactive free areas. For 
nonspecific binding studies, the concentration of the different blocking agents tested (BSA, amino-PEG, 
PLL-PEG and amino-dextran) was increased to 1 mg/mL. Experiments with nanoplasmonic biosensor 
were carried out blocking with PLL-PEG 1 mg/mL. 
2.4. Protein Biomarker Analysis  
Once immobilization process was finished, running buffer was changed to PBS and target  
detection was carried out. Protein samples were dissolved in PBS at different concentrations and 
injected in the system. For direct detection in biological samples, running buffer and dilution buffer 
were changed to PBST 0.5%. Regeneration of the antibody-immobilized surface took place by 
injecting 5 mM HCl solution.  
Calibration curves were obtained measuring different concentration of target proteins by triplicate, 
considering the % ΔRpp as signal response in the case of SPR measurements or the ΔλLSPR when using 
the nanoplasmonic biosensor. Curves were fitted through a non-linear one-site total binding function. 
Limit of detection (LOD) for each analyte was determined from the linear regression of the linear 
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range of the calibration curve, as the concentration corresponding to the minimum measurable signal, 
set as three times the standard deviation of the blank signal. 
3. Results  
3.1. Comparison of Antibody Immobilization Strategies  
Three different antibody-immobilization strategies were compared: Prolinker™ strategy (see Figure 1), 
covalent binding of the antibody, and Protein-G-based coupling. Human chorionic gonadotropin (hCG) 
hormone and its respective specific monoclonal antibody (mAb anti-hCG) were initially used as the 
model pair to carry out the study. First, different antibody concentrations, between 5 and 100 µg/mL 
were tested in order to compare the coupling efficiency. As can be observed in Figure 2a, Protein G 
and ProLinker™ strategies showed higher signal response, being the ProLinker™ 10 times higher than 
the covalent method using the same concentration of antibody, which indicates a significant higher 
antibody binding efficiency.  
Figure 1. ProLinker™ strategy (a) Immobilization protocol: (i) surface coating with 
ProLinker™ B; (ii) antibody immobilization and blocking step with bovine serum albumin 
(BSA); and (iii) specific antigen detection; (b) Proposed mechanism for antibody capturing 
by ProLinker™ molecule. Main contribution to coupling is attributed to the host-guest 
interaction between ionized amino groups from the protein and the crown-ether moiety. 
Hydrophobic interactions between methoxy group of the linker and hydrophobic residues 
of the protein are also involved. End-on orientation is induced by dipole-dipole interactions. 
Figure adapted from [14,17]. 
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Figure 2. (a) Comparison of antibody immobilizations at different antibody concentrations 
(5, 10, 20, 50, 100 µg/mL) with different strategies. Grey: covalent strategy; Green: Protein G 
strategy ([Protein G] = 50 μg/mL); Purple: ProLinker™ strategy; (b) Antigen detection 
performed with hCG/anti-hCG for covalent strategy (black), Protein G strategy (green) and 
ProLinker™ strategy (purple). Concentration of anti-hCG antibody was 10 µg/mL in all 
cases. Dashed lines represent adsorption of nonspecific proteins onto antibody functionalized 
surfaces for covalent strategy (black), Protein G strategy (green) and ProLinker™ strategy 
(purple). Blue dotted line indicates additional control for the ProLinker™ strategy,  
based on the detection of hCG onto a nonspecific antibody (10 µg/mL) immobilized over 
ProLinker™ layer (same experimental conditions as with specific antibody).  
 
Sensitivity and specificity for hCG detection were evaluated and compared. An antibody concentration 
of 10 μg/mL was selected. The target binding with Prolinker™ strategy was considerably higher compared 
with Protein G and covalent approaches (See Figure 2b). The LOD achieved in each case reflected  
the better sensitivity of the Prolinker™ strategy (LOD = 106 ng/mL, R2 = 0.9647) compared with the  
Protein G (LOD = 427 ng/mL, R
2
 = 0.9993) and covalent strategy (LOD = 372 ng/mL, R
2
 = 0.9647). 
The specificity of the antigen detection was also evaluated by performing assays with non-target 
control proteins (BSA and prostate specific antigen (PSA)) at different concentrations (see Figure 2b). 
No significant binding was observed with any of the three strategies and confirmed that signal 
contribution comes only from specific detection of the corresponding target. In the particular case of 
ProLinker™ strategy, an additional specificity test was performed, based on the immobilization of a 
non-specific antibody. Further injection of target protein (hCG) resulted in no signal. 
Immobilization strategies were further assessed for the direct detection of two protein disease 
biomarkers, the focal adhesion kinase (FAK) and C-Reactive Protein (CRP) and similar results were 
observed. Thus, under same assay conditions (i.e., [Antibody] = 10 µg/mL) ProLinker™ strategy showed 
higher antibody immobilization signal for both antibodies (% ΔRpp(CRP) = 5.18, % ΔRpp(FAK) = 7.17), 
compared with Protein G approach (% ΔRpp(CRP) = 2.08, % ΔRpp(FAK) = 1.95). As can be seen in 
Figure 3, calibration curves for CRP and FAK biomarkers clearly showed also better sensitivities using 
ProLinker™, with LOD of 86 ng/mL (R2 = 0.9799) and 23 ng/mL (R2 = 0.9718) for FAK and CRP, 
respectively, when compared with the Protein G strategy at the same antibody concentration 
(LOD(FAK) = 208 ng/mL (R
2
 = 0.9895) and LOD(CRP) = 42 ng/mL (R
2
 = 0.9977)).  
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Figure 3. Calibration curves for (a) FAK protein and (b) CRP protein, performed  
with 10 µg/mL of specific antibody and following both Protein G strategy (green) and 
ProLinker™ strategy (purple). Dashed red lines represent linear fit of the linear region of 
the curves. 
 
3.2. Stability and Robustness of the Direct Label-Free Immunoassay 
The regeneration capability for the Prolinker™ strategy was evaluated by removing target proteins 
from the antibody-immobilized layer using acidic conditions (HCl 5 mM) and injecting right after the 
same target concentration. Experiments were performed with PBS and PBST buffer. In both cases, 
complete removal of target protein was observed without altering the amount of antibody on the 
surface (see Figure 4a), although a better stability was obtained when using PBST (up to 20 cycles) 
instead of PBS (up to 7 cycles). 
Figure 4. (a) Sensogram of biosensing measurement with ProLinker™-coated surface: 
antibody immobilization (anti-CRP 10 µg/mL), blocking step (BSA 1 mg/mL), antigen 
detection (CRP 1 µg/mL) and regeneration (HCl 5 mM); (b) Detection cycles performed 
by consecutive interaction of specific target at 1 µg/mL and regeneration with HCl 5 mM 
using PBS in flow; (c) Detection cycles performed by consecutive interaction of specific 
target at 1 µg/mL and regeneration with HCl 5 mM using PBST in flow.  
 
  
Sensors 2014, 14 2247 
 
 
3.3. Biological Samples Analysis 
Experiments with undiluted urine samples were done to assess the behavior of ProLinker™-based 
antibody layer. The experiments were done with the CRP protein. CRP immunoassays were carried out 
with PBST 0.5% as the running buffer. Injection of pure urine absent of protein resulted in no 
background (see Figure 5a), which confirms the lack of nonspecific binding onto the biofunctionalized 
surface. Calibration curves for CRP-spiked urine showed comparable sensitivities to the ones obtained 
with standard buffer conditions demonstrating that urine components did not hinder the immunochemical 
reaction (see Figure 5b). While the LOD in PBS and PBST was 23 ng/mL (R
2
 = 0.9718) and 22 ng/mL 
(R
2
 = 0.9747) respectively, a very close value was reached with pure urine (LOD = 26 ng/mL  
(R
2
 = 0.9973). Furthermore, regeneration with the previously selected conditions resulted in similar 
number of cycles (up to 20 measurements) without signal loss. 
Figure 5. (a) SPR sensograms for pure urine spiked with different CRP concentrations  
(b) Calibration curves for CRP detection using ProLinker™ strategy with 10 µg/mL of 
specific antibody and performed in: PBS (black), PBST 0.5% (purple) and undiluted urine 
(orange); (c) Serum nonspecific adsorption onto sensor surface blocked with different 
agents (BSA, amine-dextran, diamine-PEG and PLL-PEG) diluted 1:10 with different 
buffers (PBS, PBS + 1%BSA, SuperBlock
®
, PBST 0.5% and HBB buffer).  
 
Undiluted human serum was tested over a ProLinker™-based bioactive surface (i.e., Prolinker™ 
layer with CRP antibodies immobilized and blocked with BSA). We observed a significant increase of 
signal caused by nonspecific binding (data not shown). In order to minimize this effect, an optimization 
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study was carried out, initially with diluted serum, consisting of (i) evaluating surface blocking with 
different antifouling compounds (BSA, amine-dextran, diamine-PEG and PLL-PEG) and (ii) changing 
buffer compositions used to dilute the serum. Figure 5c summarizes the results when these parameters 
were tested using serum at 10%. The non-specific binding could be reduced up to 94% using HBB 
buffer and PLL-PEG as blocking agent, in comparison with the standard conditions (PBS buffer and 
BSA as blocking agent). 
3.4. Gold Nanodisks Measurements  
The Prolinker™ strategy was evaluated on a gold nanodisks surface. We employed a homemade 
nanoplasmonic biosensor based on the LSPR of gold nanodisks when illuminated at a fixed angle of 
incidence (70°) [15]. Tracking the displacements of λLSPR caused by changes in the RI of the 
surrounding medium, enables monitoring biological events that take place on the gold nanodisks 
surface. By changing the sensor surface and the polarization of the light (i.e., TM for gold film and TE 
for gold nanodisks), this biosensing device allows working in both SPR and LSPR configurations. 
Hence, a reliable comparison between both biosensing approaches could be performed. We have 
implemented the ProLinker™ strategy to functionalize nanoplasmonic substrates based on the initial 
results obtained with plain gold films in SPR (see Figure 6a). Several antibody concentrations were 
evaluated (10, 20 and 50 μg/mL). The antigen detection curves obtained with the different antibody 
concentrations showed increasing signals when higher amount of receptor was immobilized (Figure 6c). 
We selected an antibody concentration ([Antibody] = 20 µg/mL) to continue with the study. Calibration 
curves performed under same conditions (same antibody concentration and PLL-PEG as blocking 
agent) for both SPR and LSPR biosensing schemes were carried out (see Figure 6d) reaching LODs of 
LOD(SPR) = 30.8 ng/mL (R
2
 = 0.9859) and LOD(LSPR) = 16.2 ng/mL (R
2
 = 0.9950). 
Figure 6. (a) Immobilization protocol for gold nanodisks substrates: (i) ProLinker™ layer 
formation; (ii) Antibody immobilization and blocking step with PLL-PEG; and (iii) Specific 
antigen detection; (b) Scanning electron microscopy (SEM) images of gold nanodisks 
fabricated by hole-mask colloidal lithography (c) CRP detection curves performed  
with the nanoplasmonic biosensor at different concentrations of antibody immobilized  
(10, 20, 50 µg/mL) with ProLinker™ strategy; (d) Calibration curves for CRP detection 
performed on gold film (orange) and gold nanodisks nanoplasmonic (blue). Antibody 
concentration was 20 µg/mL and PLL-PEG was employed as blocking agent for both 
substrates. Dashed lines represent linear fit of linear region; (e) Nonspecific adsorption study 
of serum at different concentrations (10%, 25%, 50%, 100%) using different buffers in flow 
(PBST 0.5% and HBB) performed for both sensor substrates: SPR gold film (orange) and 
LSPR gold nanodisks (blue). 
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We compared the behavior of both sensor surfaces (gold film and gold nanodisks) for nonspecific 
adsorption of serum at different dilutions (10%–100%) when using PLL-PEG as blocking agent and 
those buffers that showed best results in previous experiments with SPR (i.e., PBST 0.5% and HBB). 
Results plotted in Figure 6e showed a significant minimization of nonspecific binding onto the 
nanodisks substrates compared to the gold film surface when using HBB buffer in flow. A 90% reduction 
of the matrix adsorption was observed when injecting undiluted serum onto the biofunctionalized gold 
nanodisks. Similar results were observed with all the serum solutions. 
4. Discussion 
4.1. Assessment and Optimization of Antibody Immobilization Strategy  
In biosensing, the achievement of best analytical features strongly depends on the sensor surface 
biofunctionalization. For label-free detection based on antibody recognition, the right orientation of the 
biomolecule becomes crucial. Among the myriad of antibody immobilization procedures reported, the 
one based on ProLinker™ molecule offers important advantages in terms of simplicity, site-specific 
capture and no chemical manipulation of the biomolecule. Although it has been previously compared 
with other strategies using fluorescence-based arrays [18], the strategy has not been optimized in-depth 
for label-free biosensing. This calixarene-derivative molecule forms a dense layer on gold surfaces by 
thiol chemisorption and proteins can subsequently specifically bind. The proposed mechanism attributes 
the major coupling force to a host-guest interaction between ionized amine groups of the protein and 
the crown-ether moiety of the linker [17]. In fact, the interaction of the ProLinker™ with several  
α-aminoacids has been reported [19] indicating that Ala and Val establish strong interactions due to 
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spherical effects. Also strong and stable complexes are formed with Arg and Lys, by means of 
electrostatic interactions. These interactions ensure the formation of strong complexes with aminated 
proteins such as antibodies. In this particular case, hydrophobic interactions between the hydrophobic 
residues of the immunoglobulin, present in the Fc region, and methoxy groups of the ProLinker™ may 
also be involved in the immobilization, inducing a vertically oriented capture (see Figure 1b). A 
possible mechanism for the orientation of the antibodies onto the ProLinker™ layer was given by 
Chen et al. [17]. It is generally assumed that antibodies present a dipole momentum pointing from Fc 
to (Fab)2 fragment due to differences in the isoelectric point between the two regions [20]. Hence, 
according to the direction of the ProLinker™ dipole and antibody dipole, the immobilized antibody in 
an end-on orientation can interact with the ProLinker™ layer with lower energy than with other 
orientations. Accordingly, the sum of hydrophobic, host-guest and dipole-dipole interactions participating 
in antibody coupling will predictably confer both highly stable attachment and proper orientation. 
Thus, in order to evaluate the efficacy of the ProLinker™ strategy (see Figure 1) to immobilize 
antibodies we performed a comparative test with two other conventional strategies: covalent binding to 
an alkanethiol SAM and affinity capture by Protein G layer. Particularly, the comparison study was 
focused on evaluating not only the improvement that can be achieved when appropriately orienting the 
antibody layer but also on evaluating the simplicity and the potential of the methodologies to generate 
stable and robust biofunctionalized sensor surfaces. Covalent immobilization strategy was selected as 
reference of a standard and commonly used procedure that generally leads to randomly oriented layer 
of antibodies. It inherently generates high biosurface stability and allows the control of the packing 
density although it usually requires high concentration of antibody, between 0.1 and 1 mg/mL [21,22]. 
Protein G (or Protein A)-mediated immobilization strategy has been extensively used in the biosensing 
field [23,24]. It shows high efficiency to appropriately orientate the antibodies although from an 
immobilization point of view it requires more steps, involving SAM formation, the attachment of the 
Protein G and subsequent binding of antibodies. Meanwhile, although the affinity is quite good [25,26], 
the dissociation Protein G/A–antibody occurs at extreme pH values, which usually are the conditions 
also required in regeneration steps to remove target from antibody. In order to generate a bioactive 
surface with potential for reusability, we used a crosslinker (BS
3
), which covalently binds the antibody 
to the Protein G molecules [27,28]. On the other hand, ProLinker™ immobilization strategy is a 
simple and rapid procedure that does not require any chemical modification or previous manipulation 
of the antibodies (see Figure 1a), which minimizes possible deterioration of the antigen affinity. 
Moreover, as the stability and robustness of the ProLinker™-based layer has not been so far reported 
we not only evaluated the final sensitivity but we completed the evaluation by assessing both reusability 
and reproducibility of the biosurface. We performed initial experiments with hCG hormone, a reported 
tumor biomarker in some cancer types such as prostate cancer, testicular cancer, breast or ovarian 
cancer [29,30], besides being the gold diagnostic marker for most pregnancy tests.  
From the results obtained after comparing the three strategies (Figure 2), where the antibody was 
immobilized in a much higher extent with both ProLinker™ and Protein G strategy, we can confirm 
the coupling mechanism via affinity interaction leads to a more efficient binding. It is noteworthy that 
conventional covalent attachment resulted in very low amount of antibody on the surface (according to 
the low signals obtained). This is because EDC/NHS approach renders usually low yield of coupling 
basically due to the low density of formed NHS-esters even considering high excess of reagents. 
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Further experiments were done with a fixed antibody concentration of 10 μg/mL, which is a relatively 
low concentration, considering that reported direct immunoassays usually employ concentrations 
around 100 µg/mL [31] or even higher [22]. hCG detection was performed and as can be seen in 
Figure 2b, the target binding in the ProLinker™ strategy was considerably higher compared with 
Protein G and covalent approaches. These results seem to indicate that ProLinker™ strategy provides 
an oriented antibody layer with presumably good accessibility to the active binding sites. It is worth 
mentioning the low detection signal observed with the Protein G-based methodology. Similar response 
was observed with the covalent binding, although the amount of antibody in the surface was clearly 
higher (about ~11 times as can be deduced from the immobilization step). Moreover, with the Protein G 
the antibody should be arranged in theory in a more oriented distribution. This might be due to the 
crosslinking step introduced to stabilize the antibody-Protein G interaction. The crosslinking procedure 
consists of the formation of covalent bonds between free amine groups that are in close contact by 
means of BS
3
, which contains two succinimidyl groups. Amino groups of the binding sites can also 
suffer this cross-linking, leading to structural alterations in those areas, thereby reducing their 
biological activity and affinity [27]. A LOD for hCG of 106 ng/mL was reached with the ProLinker™ 
strategy, which would be sufficient for clinical applications (Normal concentration of hCG in men and 
non-pregnant women ranges from 0–5 IU/L (≈1 ng/mL)[32] and can increase to the μg/mL range [29]).  
Regarding the specificity studies, control experiments were carried out using non-target proteins to 
assess their binding over the antibody-coated surfaces. Results summarized in the Figure 2b indicated 
negligible binding in all cases for the same range of concentrations than the target hCG. An additional 
specificity test was performed for the ProLinker™ strategy. As described before, the crown-ether 
moiety present in the structure couples proteins via free amine groups and, in fact, a blocking step with 
amino-containing molecules such as BSA is necessary to cover free ProLinker™ spaces on the  
surface (see Figure 1a). Therefore, in order to discard a direct binding of the target molecule onto the 
ProLinker™ itself, an evaluation of the cross-reactivity of the target protein to a nonspecific-previously 
immobilized-antibody was performed. Results depicted in Figure 2b confirmed the high specificity  
of the assay. As can be seen, the protein (hCG) does not bind to any component on the surface unless  
its specific antibody is present, showing a significant decrease in the response compared with the 
corresponding specific layer. 
Besides hCG, two additional proteins with clinical significance as biomarkers were tested, FAK and 
CRP. FAK is an intracellular protein which plays an important role in cell growth and regulation. It is 
one of the principal molecules involved in cancer cell metastasis regulation and is associated with 
aggressive tumor behavior. It is known that FAK overexpression contributes to the development of 
typical features of malignancy in many tumors and its early detection has become a key factor in 
cancer diagnosis and therapy [33,34]. CRP is a widely studied marker of inflammation and infection 
and it is also used in heart disease risk assessment, progression and treatment effectiveness [35]. It has 
been also recently reported that detection of low levels of CRP in urine may be useful for the diagnosis 
of lower urinary tract symptoms (LUTS) [36]. Thus, detection of both biomarkers can be relevant  
and exemplifies two useful applications where direct detection in serum or urine is necessary. As 
summarized in the Results section (see Figure 3), in both cases LOD in the ng/mL were obtained with 
the ProLinker strategy (86 ng/mL for FAK and 23 ng/mL for CRP). Whereas no clinical ranges have 
been so far reported for FAK, for CRP it is well known that its concentration in human serum in 
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healthy patients is usually lower than 10 µg/mL and it can increase to higher levels in case of 
inflammation, and viral or bacterial infections (10–200 µg/mL) [37]. Thus, the sensitivity achieved 
with this procedure is sufficient for its direct detection.  
In order to complete the study, additional experiments were carried out to further assess the stability 
of the antibody-coated surface. It is particularly important to ensure the reusability of the sensor in case 
this might be necessary, either to lengthen the surface life-time, to save costs or to study the reproducibility 
and optimization protocols. As commented above, to our knowledge, this issue has not been addressed 
with ProLinker™-coated surfaces. Regeneration cycles (i.e., injection of target and removal with acid 
conditions) were done and the corresponding signals were measured. Considering that antibody 
coupling to the ProLinker™ layer does not involve any covalent bond but host-guest interaction  
(i.e., high affinity electrostatic interaction), an a priori partial loss of antibody on the surface could be 
expected under extreme pH conditions. Also a certain decrease of activity of the remaining bound 
antibody would be likely. Remarkably, we observed a complete removal of target protein without 
altering the amount of antibody on the surface (see Figure 4a), and retaining its activity with good 
levels of reproducibility. Assays with PBS as running buffer resulted in good repeatability until the 
seventh cycle (see Figure 4b); then a loss around 60% of the detection signal was observed and kept 
decreasing exponentially in subsequent measurements. It is worth mentioning that these results are 
considered normal in solid-based direct immunoassays, even when using covalent coupling, due to the 
limited stability of antibodies in aggressive mediums such as pH changes. Same experiments were then 
carried out with PBS buffer containing Tween 20. This additive is a surfactant widely used to reduce 
nonspecific binding events [38] and is usually added in conditions where detection in biological 
samples is the final purpose. Surprisingly, when assays were performed over ProLinker™-based 
surfaces with PBST (PBS with 0.5% of Tween 20) the stability of the biosurface was greatly increased, 
making it possible to perform up to 20 direct detection cycles with high reproducibility before reaching 
a 40% decrease of the signal (see Figure 4c). 
From the above results, and given the high simplicity and better sensitivity obtained with 
ProLinker™ methodology without worsening the stability or biological activity, we continued with the 
assessment using biological fluids (urine and serum). We decided also to continue with CRP as protein 
target for this evaluation since its direct and high sensitive detection from both human fluids has 
important significance for several disease diagnosis and clinical relevant concentrations are already 
reported in the literature. 
4.2. Direct Label-Free Immunoassay in Biological Samples  
Protein biomarkers analysis is crucial in clinical diagnosis and their direct detection from biological 
fluids is a required demand. This analysis may become especially complex due to interferences and 
undesired nonspecific adsorption of matrix components present in urine, serum or whole blood. In case 
of label-free detection and in particular in optical biosensors, where signals are directly related with 
mass changes on the sensor surface, this must be minimized. 
Urine is an ideal sample for disease biomarker determination as it can be obtained in large amounts 
with non-invasive methods. Human urine consists primarily of water with organic solutes, such as urea 
or creatinine, inorganic ions to a much less extent, also small organic substances and metabolites, 
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enzymes or proteins [39]. Hence the urine matrix effect in direct analysis might be less severe than 
serum or plasma, where considerably higher concentrations of proteins are present. However, a high 
salt content like the one in urine samples may interfere in the immunochemical interaction. Potential 
nonspecific adsorptions cannot be discarded either [40]. Undiluted urine was initially tested. The 
running buffer selected for these experiments was PBST 0.5%, which provides high stability to the 
bioactive layer and its elevated surfactant concentration might minimize nonspecific interactions. 
Results in Figure 5a indicate that no components of the urine bind to the surface (no signal after 
addition of pure urine). Figure 5b shows calibration curves in PBS, PBST and pure urine and only 
slight differences were observed, leading to very similar LODs of ~20 ng/mL. These results demonstrate 
that urine components did not hinder the immunochemical reaction. Overall, these positive results even 
with pure urine corroborate the robustness and the stability of not only the antibodies but also of the 
ProLinker™-based layer, resulting in an interesting candidate for the development of direct assays 
with views of applying in point-of-care devices. 
Most protein biomarkers are not excreted in the urine but appear in blood and in those cases 
analysis of serum, plasma or whole blood is the best minimum invasive alternative. Direct analysis of 
undiluted serum (or whole blood) still remains as a challenge in direct label-free biosensing. The high 
amounts of proteins and lipids present in blood, which can be adsorbed onto the sensor surface, usually 
lead to high background signal and in the case of immunochemical interactions can also interfere in the 
antigen recognition. Undiluted human serum was first tested over the ProLinker™-antibody-BSA 
blocked layer and indeed we observed a significant nonspecific binding (data not shown). Thus we 
carried out an optimization study with diluted serum (10% in buffer) focused on removing the 
undesired adsorption. Two parameters were selected: (i) changing the blocking agent and (ii) changing 
the buffer composition in which the serum is diluted. The composition of the buffers is based on the 
blocking effect of certain compounds such as BSA or dextran, and on the presence of surfactants such 
as Tween 20, which reduces the nonspecific binding events. On the other hand, the blocking surface 
protocol was modified to include the use of antifouling compounds, such as PEGylated or dextran 
derivatives as blocking agents. These polymers are widely used in biomedicine because of their protein 
adsorption resistance and biomimetic properties [41]. In the ProLinker™ strategy, BSA is used as 
blocking agent to cover the remaining ProLinker™ groups with no antibody (free crown moiety of 
ProLinker™ will interact with amino groups present in the protein). By substituting BSA with other 
amine-containing compounds with more biocompatible and hydrophilic properties such as PEG/PLL-PEG 
and diamine-PEG) or dextran (amine-dextran), we would expect an improved behavior of the surface 
against serum.  
As it can be seen in Figure 5c the presence of surfactants in the dilution buffer helps reducing  
the adsorption of serum components onto the surface (i.e., PBST and HBB buffer) while the use of  
PLL-PEG offers a significant improvement in the antifouling resistance. A possible reason for this 
better behavior when compared with diamine-PEG may lie in the higher molecular weight and the 
relative high ratio of amine groups present in the poly-L-lysine chains of the PLL-PEG that could more 
efficiently cover free ProLinker™ molecules and at the same time could confer high hydrophilicity to 
the bioactive layer. The combination of PLL-PEG for surface blocking and HBB buffer [42], which 
contains blocking agents such as BSA and dextran and high salt and Tween 20 concentration, allowed 
a reduction of the nonspecific binding of diluted serum of 94% with respect to standard conditions 
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(BSA as blocking agent and PBS buffer). These promising results can be considered a first approach in 
order to improve the conditions that permit working with more concentrated serum, or ideally with 
pure serum samples.  
4.3. ProLinker Strategy Applied to Nanoplasmonic-Based Biosensor  
Motivated by miniaturization and multiplexing possibilities, nanoplasmonic biosensors are considered 
the next-generation label-free plasmonic sensors. However, a key factor on their final development is 
related to the surface biofunctionalization. Nanoplasmonic sensing configurations can offer important 
benefits in terms of sensitivity and selectivity, but the transfer of conventional gold surface chemistry 
to nanostructured substrates implies additional factors, such as the substrate effects or the stronger  
field confinement [3], which must be taken into account when optimizing the overall performance of 
the biosensor. 
Thus, we evaluated the behavior of the Prolinker™ strategy on gold nanodisks. We employed a 
homemade biosensing device which can operate both in SPR and LSPR configurations, therefore 
allowing a more accurate comparison between isolated nanodisks and a continuous thin gold gold 
layer. We followed an analogous immobilization procedure for the nanodisks (see Figure 6a), although 
taking into account the dual nature of the substrate (gold nanodisks on a glass layer).  
We attempted a material-selective surface functionalization by exploiting the use of PLL-PEG as 
blocking agent. This compound has high affinity for glass surfaces [43]. Coating with PLL-PEG 
allowed us both the passivation of the glass surrounding the gold nanodisks and the additional 
blocking process of free ProLinker™ molecules (as previously observed on gold). Thus, in this way, 
we can generate a highly hydrophilic layer onto the sensor surface, increasing the resistance to 
nonspecific protein adsorption.  
Gold nanodisks substrates offer a reduced active sensor surface when compared to thin gold films 
used in SPR biosensors (nanodisk substrates have an approximate surface occupation of 6%–7%) (see 
Figure 6b) [15]. Therefore, one would expect an increase of the required antibody concentration to 
obtain optimum antigen detection signals compared with SPR. Thus, different anti-CRP concentrations 
(10, 20 and 50 µg/mL) were immobilized on gold nanodisks following the same experimental 
procedure used in SPR device. The antigen detection curves obtained showed increasing signals when 
higher amount of receptor was immobilized (Figure 6c). Whereas an antibody concentration of 10 µg/mL 
showed similar results than 20 or even 50 µg/mL for SPR (data not shown), in the case of nanodisks, it 
was necessary to increase to at least 20 µg/mL to obtain better signals see Figure 6c). As seen in Figure 6d 
standard SPR chips showed a slightly better recognition capacity at high analyte concentration, 
probably due to the higher amount of antibodies immobilized on the gold film with respect to the gold 
nanodisks surface. However, at lower concentrations of antigen, the detection performed with the gold 
nanodisks provided better sensitivity, (i.e., a more pronounced slope for LSPR curve than for SPR) 
resulting in a two-times better detectability (LOD(SPR) = 30.8 ng/mL and LOD(LSPR) = 16.2 ng/mL). 
This result could be partially ascribed to the strong LSPR field confinement of the nanodisks 
(compared to SPR), which becomes more evident at low target concentrations.  
Finally, we performed a nonspecific binding study in order to evaluate the benefits of the 
nanostructured substrates for reducing undesired matrix adsorptions from biological fluids. We 
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selected the serum in order to improve the obtained SPR results as much as possible. We tested different 
serum dilutions and serum 100%, using the two buffers with better output in SPR (PBST 0.5% and 
HBB). In comparison with the gold surface, a high reduction of the nonspecific adsorption was 
observed for the gold nanodisks in all the serum dilutions, even also in serum 100%, when using HBB 
buffer). Indeed, a 90% less nonspecific binding with pure serum was achieved when HBB was the running 
buffer. This result definitely brings out the exceptional advantages of nanoplasmonic biosensors for the 
direct detection of protein biomarkers. Material-selective functionalization can strongly minimize 
nonspecific fouling, thereby guaranteeing reliable label-free analysis in biological samples.  
5. Conclusions/Outlook 
The use of ProLinker™ as orienting molecule for antibody immobilization has been optimized for 
SPR biosensing and afterwards implemented on a novel nanoplasmonic biosensor showing great 
potential for direct immunoassay of protein biomarkers in biological fluids. This strategy turned out to 
be highly efficient for antibody coupling in an oriented manner with a relatively low consumption of 
reagent, resulting in higher analysis sensitivity in respect to more conventional methodologies.  
The bioactive surface generated was stable enough to allow reusability to a quite remarkable extent  
(up to 20 detection cycles) without the need of extra stabilization steps. The strategy offers same 
results regardless the antibody/target considered, proving its versatility for different targets. Moreover, 
ProLinker™-based layer allows direct immunoassay in undiluted urine samples avoiding nonspecific 
adsorption while retaining same sensitivity than in standard clean buffer conditions. These results 
demonstrate the robustness of the strategy even in more complex matrices and including also 
regeneration of the biological surface. A new approach based on the use of antifouling PEGylated 
compounds, particularly the copolymer PLL-PEG, instead of BSA as blocking agents, has shown 
encouraging results addressed to reduce undesired nonspecific binding events with serum, while 
retaining target detection’s capability. This has been particularly remarkable with gold nanodisks 
surfaces. The high immobilization efficiency together with the high reproducibility and stability of the 
bioactive surface fulfill important requirements for label-free biosensor-based immunoassays. Overall, 
the implementation of the ProLinker™ strategy to gold nanodisks also highlights its exceptional 
potential for nanoplasmonic biosensing, additionally benefiting from the sensitivity improvements 
LSPR can offer.  
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